The US Collaborative Review of Sterilization reported reduced menstrual bleeding and pain and increased cycle irregularity after tubal ligation ([@bib10]). These findings provided evidence against a 'post-tubal ligation syndrome\' that included dysmenorrhoea and menorrhagia, but could not address long-term outcomes, such as altered menopausal age ([@bib12]), symptoms ([@bib15]; [@bib16]; [@bib8]), or breast cancer risk.

A recent meta-analysis reported no association between tubal ligation and breast cancer (RR=0.97); however, substantial heterogeneity between studies (*I*^2^=82.2%, *P*\<0.001) was observed. Effect estimates among eight studies ranged from RR=0.37 (0.19, 0.68) to 1.20 (1.00, 1.30) ([@bib3]). This variability may be partly due to incomplete information on subsequent gynaecologic surgeries and tumour subtypes. Women who have a tubal ligation are more likely to undergo hysterectomy ([@bib5]), which may include bilateral oophorectomy ([@bib7]), and thereby decrease breast cancer risk. Few studies have evaluated variation by tumours that express oestrogen receptor (ER) or progesterone receptor (PR) and may therefore be more sensitive to hormonal exposures ([@bib2]; [@bib13]).

We studied tubal ligation in relation to menopausal age, symptoms, and ER/PR-defined breast cancer in the Sister Study.

Materials and Methods
=====================

The Sister Study is an ongoing prospective cohort of US women who have a sister who was diagnosed with breast cancer ([@bib4]; [@bib17]). During 2003--2009, 50 884 women aged 35--74 years completed baseline telephone interviews including reproductive and medical history. All participants are asked to return brief annual health updates and comprehensive biennial questionnaires. Incident breast cancers are initially self-reported and later confirmed by medical record review. Response rates have been ⩾94% over follow-up. This research was approved by the Institutional Review Boards of the National Institute of Environmental Health Sciences, NIH, and the Copernicus Group. All participants provided informed consent.

Participants reported ever having a tubal ligation and at what age. We excluded 274 women with missing information on tubal ligation or age at tubal ligation, a breast cancer diagnosis preceding enrolment or with unknown date, or who reported tubal ligation after hysterectomy or menopause. Also excluded were 296 women (0.6%) with missing race, education, body mass index, alcohol consumption, oral contraceptive (OC) use, age at menarche, age at first birth, parity, marital status, hysterectomy, or menopausal status. Records from 50 314 women were analysed.

Women reported ever having hot flashes and at what age, and whether they ever had 'any other symptoms of menopause such as poor sleeping, night sweats, irritability, or depression\' (yes/no) and at what age. Women were considered menopausal after 12 months of amenorrhoea not due to pregnancy or breastfeeding. Age at menopause was defined as a woman\'s age at last menstrual period.

Women who reported incident breast cancer were asked to provide diagnosis details and authorise the release of medical records. Approximately 10% declined medical record release or died before providing authorisation. Agreement was high between self-reports and medical records for ER status (95%) and invasiveness (81%) ([@bib6]). When medical records were unavailable, self-reported data were used. At the time of this analysis, medical records were available for 77% of reported breast cancers.

Statistical analyses
--------------------

Prevalence ratios (PRs) and 95% confidence intervals (CIs) were calculated from multivariate log-negative binomial regression. To evaluate tubal ligation in relation to menopausal characteristics, we calculated hazard ratios (HRs) and 95% CIs using Cox proportional hazards models. Women contributed person-time from the age of 30 years to the event of interest (menopause, hot flashes, other menopausal symptoms) or were censored at the age at interview, age at uterine ablation/embolisation, age at hysterectomy, age at oophorectomy, age at tamoxifen (for chemoprevention) initiation, age at ovarian cancer, or at the age of 60 years, whichever occurred first. Model covariates were selected *a priori* based on known associations with tubal ligation or menopausal characteristics. Final models adjusted for age at interview, race, education, marital status, body mass index (BMI) during ages 30--39 years, and two time-varying covariates: average number of daily cigarettes from the age of 30--60 years and average number of alcoholic drinks per week during each decade (1930s, 1940s, 1950s). In sensitivity analyses, we adjusted for parity and postmenopausal hormone use and stratified by OC use.

For breast cancer analyses, person-time was accrued from the age at study enrolment. In tumour subtype analyses, competing or undefined subtypes were censored at the date of diagnosis. Final models adjusted for the following covariates *a priori* as potential confounders: age (as the time scale), education, race, age at menarche, parity, OC use, age at first birth, age at last birth, BMI, and alcohol consumption at enrolment. In sensitivity analyses, we controlled for postmenopausal hormone use and stratified by mammography screening.

Results
=======

Overall, 14 802 women (29.4%) reported having a tubal ligation (mean age=32.7 years; s.d.=5.5); prevalence was highest among women who reported lower education, African-American race, overweight to obese BMI, current cigarette smoking, ever OC use, younger age at first birth, and having ⩾2 births. Tubal ligation was also more prevalent among women who reported hysterectomy, postmenopausal hormone use, and mammography screening ([Table 1](#tbl1){ref-type="table"}).

Menopause
---------

Women who had a tubal ligation were 9% more likely to report hot flashes (95% CI: 1.06--1.12) and 10% more likely to have other symptoms of menopause (e.g., poor sleeping, night sweats, irritability, depression) (95% CI: 1.07--1.13) compared with women who did not have a tubal ligation ([Table 2](#tbl2){ref-type="table"}). Among those reporting symptoms, 71% had both hot flashes and other symptoms. Risk of hot flashes did not vary by age at tubal ligation, although other menopausal symptoms appeared more frequent at older ages (HR 1.15: 95% CI: 1.11--1.20 for tubal ligation ⩾35 years *vs* HR 1.07; 95% CI: 1.03--1.11 for \<35; [Table 2](#tbl2){ref-type="table"}). In analyses among women who never used OCs or additionally adjusted for parity or postmenopausal hormone use, the results were virtually unchanged (data not shown).

Breast cancer
-------------

During 203 141 person-years (mean=4.0 years), 1646 incident breast cancers were reported (1079 invasive, 422 *in situ*, 145 undefined). We observed no overall association between breast cancer and tubal ligation (HR 0.95; 95% CI: 0.85--1.06), or by timing of tubal ligation or subsequent gynaecologic surgery ([Table 3](#tbl3){ref-type="table"}).

Oestrogen receptor/PR status was available for 95% of invasive breast tumours. The HR for ER+/PR+ invasive disease after tubal ligation was 0.84 (95% CI: 0.70--1.01). Compared with women who reported no tubal ligation, hysterectomy, or bilateral oophorectomy, those who reported tubal ligation and hysterectomy with bilateral oophorectomy had a 42% decreased risk of ER+/PR+ invasive breast cancer (HR=0.58; 95% CI: 0.38--0.89). Associations with ER+/PR+ invasive tumours were unchanged by adjustment for postmenopausal hormones (data not shown). Tubal ligation was not associated with ER−/PR− invasive breast cancer.

We observed an increased risk of *in situ* breast cancer associated with tubal ligation within the past 10 years (HR 2.12; 95% CI: 1.20--3.73). Among women who reported having a screening mammogram within 12 months of enrolment, this association was no longer statistically significant (HR 1.87; 95% CI: 0.96--3.62; [Supplementary Table](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Women who had a tubal ligation were ∼10% more likely to report menopausal symptoms. Tubal ligation did not alter menopausal age or overall breast cancer risk. We observed a decreased risk of ER+/PR+ invasive breast cancer associated with tubal ligation among women who also had a hysterectomy with bilateral oophorectomy.

In controlled studies, the majority report a higher prevalence of hot flashes among women with prior tubal ligation ([@bib14]; [@bib15]; [@bib16]). A study of 3650 postmenopausal women in the United Kingdom reported a 38% increase (95% CI: 1.02--1.87) in the odds of menopause before the age of 49 years among women who reported tubal ligation ([@bib12]); we did not observe an association between tubal ligation and menopausal age.

Our analysis is one of few to evaluate breast cancer risk according to ER/PR status ([@bib2]; [@bib13]) or *in situ* disease. Previous studies were often unable to account for subsequent hysterectomy, which probably contributes to heterogeneity between reports ([@bib3]). In our data, decreased breast cancer risk after tubal ligation appeared largely limited to women who also underwent bilateral oophorectomy and to hormonally responsive disease.

Strengths include our large sample and detailed reproductive and lifestyle information. We reconstructed life events from the age of 30 years to interview and used time-varying exposures. Limitations include potential misclassification based on self-reported information. However, in previous studies, hysterectomy and oophorectomy status have been reliably reported ([@bib1]; [@bib11]; [@bib9]). All exposure information was reported before diagnosis and was therefore unlikely to bias our results. Subgroup analyses of incident breast cancers were constrained by small numbers, and diagnoses not reported by participants would not have been captured. Our results were robust to covariate selection; however, we cannot exclude the possibility of residual confounding.

In our study, women who had a tubal ligation were more likely to report menopausal symptoms; however, tubal ligation alone did not influence menopausal age or breast cancer risk.
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###### PRs and 95% CIs for tubal ligation

                                               **Tubal ligation**   **No tubal ligation**                   
  ------------------------------------------- -------------------- ----------------------- -------- ------- -------------------
  Total                                              14 802                 100.0           35 512   100.0          N/A
  Age at tubal ligation, mean years (s.d.)            32.7                  (5.5)            N/A      N/A           N/A
  Tubal ligation performed at last birth              4066                  27.5             N/A      N/A           N/A
  Age at study enrolment, mean years (s.d.)           55.9                  (8.0)            54.9    (9.3)   1.01 (1.01, 1.01)
  **Education**                                                                                             
  Less than HS                                        241                    1.6             374      1.1    1.62 (1.47, 1.79)
  HS diploma or equivalent                            2614                  17.7             4471    12.6    1.53 (1.47, 1.58)
  Some college                                        5871                  39.7            11 120   31.3    1.45 (1.40, 1.49)
  4-Year college degree or higher                     6076                  41.0            19 547   55.0            1
  **Race**                                                                                                  
  Non-Hispanic White                                 11 802                 79.7            30 352   85.5            1
  Black                                               1910                  12.9             2595     7.3    1.54 (1.48, 1.60)
  Latina                                              667                    4.5             1670     4.7    1.04 (0.97, 1.11)
  Other                                               423                    2.9             895      2.5    1.16 (1.07, 1.25)
  **Body mass index (kg m^−2^)**                                                                            
  \<18.5                                              123                    0.8             438      1.2    0.88 (0.75, 1.03)
  18.5--24.9                                          4659                  31.5            14 025   39.5            1
  25.0--29.9                                          4939                  33.4            11 036   31.1    1.22 (1.18, 1.27)
  ⩾30.0                                               5081                  34.3            10 013   28.2    1.34 (1.29, 1.38)
  **Smoking**                                                                                               
  Never                                               7552                  51.0            19 554   55.1            1
  Social                                              300                    2.0             843      2.4    0.95 (0.86, 1.04)
  Former                                              5377                  36.3            12571    35.4    1.05 (1.02, 1.08)
  Current                                             1572                  10.6             2541     7.2    1.39 (1.33. 1.45)
  Missing                                              1                     0.0              3       0.0             
  **Alcohol consumption**                                                                                   
  Never                                               572                    3.9             1344     3.8    1.00 (0.93, 1.08)
  Former                                              2480                  16.8             5151    14.5    1.11 (1.07, 1.15)
  Current                                            11 750                 79.4            29 017   81.7            1
  **Parity**                                                                                                
  0                                                   830                    5.6             8296    23.4    0.41 (0.38, 0.45)
  1                                                   1591                  10.7             5653    15.9            1
  2--3                                               10 323                 69.7            18 321   51.6    1.64 (1.56, 1.71)
  ⩾4                                                 2 058                  13.9             3242     9.1    1.75 (1.65, 1.85)
  Age at first birth, mean years (s.d.)               23.3                  (4.7)            25.4    (5.4)   0.94 (0.94, 0.95)
  Age at last birth, mean years (s.d.)                28.5                  (5.2)            29.7    (5.4)   0.97 (0.97, 0.98)
  **Oral contraceptive use**                                                                                
  Never                                               1804                  12.2             6239    17.6            1
  Ever                                               12 998                 87.8            29 273   82.4    1.45 (1.39, 1.51)
  **Hysterectomy**                                                                                          
  Never                                               9646                  65.2            24 897   70.1            1
  Ever                                                5156                  34.8            10 615   29.9    1.13 (1.10, 1.16)
  **Postmenopausal hormone use**                                                                            
  Never                                               7741                  52.3            21 132   59.5            1
  Unopposed oestrogens (E) only                       3185                  21.5             6758    19.0    1.16 (1.12, 1.21)
  Combination of E and E+P                            645                    4.4             1354     3.8    1.16 (1.09, 1.25)
  E plus P only                                       3189                  21.5             6174    17.4    1.23 (1.19, 1.28)
  Missing                                              42                    0.3              94      0.3             
  **Mammogram screening**                                                                                   
  Never                                               130                    0.9             431      1.2    0.86 (0.74, 1.00)
  Ever                                               14 672                 99.1            35 080   98.8           N/A
  Most recent \<1 year ago                           11 828                 79.9            28 662   80.7            1
  Most recent 1--2 years ago                          2296                  15.5             5109    14.4    1.07 (1.03, 1.11)
  Most recent \>2 years ago                           546                    3.7             1307     3.7    1.03 (0.96, 1.11)
  Missing                                              2                     0.0              2       0.0             

Abbreviations: 95% CI=95% confidence interval; E=oestrogen; HS=high school; N/A=not applicable; P=progestin; PR=prevalence ratio.

PRs and 95% CIs calculated from age-adjusted log-negative binomial regression models.

###### HRs and 95% CIs for menopausal symptoms and menopause

                                                     **Hot flashes**                  **Other menopausal symptoms**[a](#t2-fn2){ref-type="fn"}     **Menopause**[b](#t2-fn3){ref-type="fn"}                                                                                                
  ----------------------------------- ---------------------------------------------- ---------------------------------------------------------- ---------------------------------------------- -------------------------------------------- ---------------------------------------------- --------------------------------------------
                                       ***N***[c](#t2-fn4){ref-type="fn"}**/total**          **HR (95% CI)**[d](#t2-fn5){ref-type="fn"}          ***N***[c](#t2-fn4){ref-type="fn"}**/total**   **HR (95% CI)**[d](#t2-fn5){ref-type="fn"}   ***N***[c](#t2-fn4){ref-type="fn"}**/total**   **HR (95% CI)**[d](#t2-fn5){ref-type="fn"}
  **Tubal ligation**                                                                                                                                                                                                                                                                       
  No                                                  21 472/33 265                                              1                                              19 921/34 038                                       1                                       20 746/34 148                                       1
  Yes                                                  10 346/3 898                                      1.09 (1.06, 1.12)                                       9569/14 246                                1.10 (1.07, 1.13)                                9843/14 395                                0.99 (0.96, 1.02)
  **Age at tubal ligation (years)**                                                                                                                                                                                                                                                        
  \<35                                                  6450/8555                                        1.10 (1.06, 1.14)                                        5950/8758                                 1.07 (1.03, 1.11)                                 5855/8879                                 0.99 (0.96, 1.03)
  ⩾35                                                   3896/5343                                        1.08 (1.04, 1.13)                                        3619/5488                                 1.15 (1.11, 1.20)                                 3988/5516                                 0.99 (0.95, 1.02)

Abbreviations: 95% CI=95% confidence interval; HR=hazard ratio.

Other symptoms include, but are not limited to, ever experiencing 'poor sleeping, night sweats, irritability, and depression\' (yes/no).

The age-specific HR for postmenopausal status from the age of 30--60 years.

At the baseline interview.

Adjusted for age, race, education, marital status, body mass index, cigarette smoking, and alcohol consumption.

###### HRs and 95% CIs for breast cancer

                                                                                    **Total breast cancer**       **ER+/PR+ invasive breast cancer**       **ER−/PR− invasive breast cancer**        ***In situ*** **breast cancer**                                                                             
  ------------------------------------------------------------- ------------------ ------------------------- -------------------------------------------- ------------------------------------ -------------------------------------------- ----------- -------------------------------------------- ----------- ------------------------------------------------------------------------
                                                                 **Person-years**          **Cases**          **HR (95% CI)**[a](#t3-fn2){ref-type="fn"}               **Cases**                **HR (95% CI)**[a](#t3-fn2){ref-type="fn"}   **Cases**   **HR (95% CI)**[a](#t3-fn2){ref-type="fn"}   **Cases**   **HR (95% CI)**[a,](#t3-fn2){ref-type="fn"}[b](#t3-fn3){ref-type="fn"}
  **Overall**                                                                                                                                                                                                                                                                                                    
  **Tubal ligation**                                                                                                                                                                                                                                                                                             
  No                                                                 144 199                 1192                                 1                                       534                                       1                           109                          1                           293                                        1
  Yes                                                                 58 942                  454                         0.95 (0.85, 1.06)                               173                               0.84 (0.70, 1.01)                   47                   0.98 (0.68, 1.40)                   129                                1.10 (0.88, 1.37)
  **Age at tubal ligation (years)**                                                                                                                                                                                                                                                                              
  \<35                                                                36 283                  270                         0.98 (0.85, 1.13)                               110                               0.93 (0.75, 1.16)                   33                   1.09 (0.72, 1.66)                   66                                 0.95 (0.71, 1.26)
  ⩾35                                                                 22 658                  184                         0.92 (0.78, 1.08)                                63                               0.73 (0.56, 0.95)                   14                   0.81 (0.46, 1.42)                   63                                 1.29 (0.98, 1.71)
  **Years since tubal ligation (years)**                                                                                                                                                                                                                                                                         
  \<10                                                                 4498                   35                          1.30 (0.92, 1.84)                                7                                0.58 (0.27, 1.23)                    3                   1.37 (0.42, 4.48)                   14                                 2.12 (1.20, 3.73)
  10--19                                                              14 304                  103                         1.02 (0.83, 1.26)                                37                               0.85 (0.60, 1.20)                   12                   1.20 (0.65, 2.23)                   31                                 1.20 (0.81, 1.76)
  20--29                                                              26 399                  186                         0.86 (0.73, 1.01)                                76                               0.84 (0.65, 1.08)                   21                   0.91 (0.56, 1.48)                   56                                 1.03 (0.76, 1.38)
  ⩾30                                                                 13 741                  130                         0.86 (0.80, 1.17)                                53                               0.90 (0.67, 1.22)                   11                   0.85 (0.44, 1.62)                   28                                 0.88 (0.59, 1.33)
  **According to subsequent gynaecologic surgery**                                                                                                                                                                                                                                                               
  No tubal ligation or hysterectomy/bilateral oophorectomy            97 027                  766                                 1                                       354                                       1                           60                           1                           193                                        1
  Tubal ligation alone                                                36 742                  294                         1.01 (0.88, 1.17)                               123                               0.95 (0.76, 1.18)                   32                   1.38 (0.87, 2.18)                   74                                 1.02 (0.77, 1.35)
  Tubal ligation and hysterectomy alone                                9080                   73                          1.02 (0.79, 1.31)                                23                               0.74 (0.48, 1.14)                    6                   0.95 (0.40, 2.28)                   24                                 1.36 (0.87, 2.12)
  Tubal ligation and hysterectomy with bilateral oophorectomy         11 034                  76                          0.83 (0.65, 1.06)                                24                               0.58 (0.38, 0.89)                    8                   1.01 (0.47, 2.20)                   26                                 1.17 (0.76, 1.81)

Abbreviations: 95% CI=95% confidence interval; ER=oestrogen receptor; HR=hazard ratio; PR=progesterone receptor.

HRs and 95% CIs are calculated from multivariate Cox proportional hazards regression models and adjusted for age, age at menarche, education, race, body mass index, alcohol consumption, parity, age at first birth, age at last birth, and oral contraceptive use.

Additionally adjusted for mammography screening.
